Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial)

American Journal of Cardiology

Volumn 111, Issue 4, 2013, Pages 574-581

  Greene, Stephen J ^a   Vaduganathan, Muthiah ^b   Lupi, Laura ^c   Ambrosy, Andrew P ^d   Mentz, Robert J ^e   Konstam, Marvin A ^f   Nodari, Savina ^c   Subacius, Haris P ^a   Fonarow, Gregg C ^g   Bonow, Robert O ^a   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CHOLESTEROL; NATRIURETIC PEPTIDE RECEPTOR A; SODIUM; TOLVAPTAN; TRIACYLGLYCEROL; VASOPRESSIN;

AGED; ALBUMIN BLOOD LEVEL; ALL CAUSE MORTALITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SODIUM BLOOD LEVEL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITAL MORTALITY; HUMANS; INPATIENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; STROKE VOLUME; TRIGLYCERIDES; UNITED STATES;

EID: 84873307280     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.10.042     Document Type: Article

References (23)

1. K. Kalantar-Zadeh, G. Block, T. Horwich, and G.C. Fonarow Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure J Am Coll Cardiol 43 2004 1439 1444
2. S.D. Anker, A. Negassa, A.J. Coats, R. Afzal, P.A. Poole-Wilson, J.N. Cohn, and S. Yusuf Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study Lancet 361 2003 1077 1083
3. T.B. Horwich, and G.C. Fonarow Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS Semin Dial 20 2007 549 553
4. M. Gheorghiade, C. Orlandi, J.C. Burnett, D. Demets, L. Grinfeld, A. Maggioni, K. Swedberg, J.E. Udelson, F. Zannad, C. Zimmer, and M.A. Konstam Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study With Tolvaptan (EVEREST) J Card Fail 11 2005 260 269
5. M. Gheorghiade, M.A. Konstam, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, K. Swedberg, J.E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, and C. Orlandi Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials JAMA 297 2007 1332 1343
6. M.A. Konstam, M. Gheorghiade, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, K. Swedberg, J.E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, and C. Orlandi Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 2007 1319 1331
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
8. T.B. Horwich, M.A. Hamilton, W.R. Maclellan, and G.C. Fonarow Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure J Card Fail 8 2002 216 224
9. C.M. O'Connor, W.T. Abraham, N.M. Albert, R. Clare, W. Gattis Stough, M. Gheorghiade, B.H. Greenberg, C.W. Yancy, J.B. Young, and G.C. Fonarow Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) Am Heart J 156 2008 662 673
10. M. Gheorghiade, and R.O. Bonow Heart failure: early follow-up after hospitalization for heart failure Nat Rev Cardiol 7 2010 422 424
11. N. Afsarmanesh, T.B. Horwich, and G.C. Fonarow Total cholesterol levels and mortality risk in nonischemic systolic heart failure Am Heart J 152 2008 1077 1083
12. M. Rauchhaus, A.L. Clark, W. Doehner, C. Davos, A. Bolger, R. Sharma, A.J. Coats, and S.D. Anker The relationship between cholesterol and survival in patients with chronic heart failure J Am Coll Cardiol 42 2003 1933 1940
13. C.M. O'Connor, R.J. Mentz, G. Cotter, M. Metra, J.G. Cleland, B.A. Davison, M.M. Givertz, G.A. Mansoor, P. Ponikowski, J.R. Teerlink, A.A. Voors, M. Fiuzat, D. Wojdyla, K. Chiswell, and B.M. Massie The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction Eur J Heart Fail 14 2012 605 612
14. T.B. Horwich, A.F. Hernandez, D. Dai, C.W. Yancy, and G.C. Fonarow Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure Am Heart J 156 2008 1170 1176
15. C.H. Yoon, T.J. Youn, S. Ahn, D.J. Choi, G.Y. Cho, I.H. Chae, J. Choi, H. Cho, S. Han, M.C. Cho, E.S. Jeon, S.C. Chae, J.J. Kim, K.H. Ryu, and B.H. Oh Low serum total cholesterol level is a surrogate marker, but not a risk factor, for poor outcome in patients hospitalized with acute heart failure: a report from the Korean Heart Failure Registry J Card Fail 18 2012 194 201
16. M. Rauchhaus, V. Koloczek, H. Volk, M. Kemp, J. Niebauer, D.P. Francis, A.J. Coats, and S.D. Anker Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure Int J Cardiol 76 2000 125 133
17. H.T. May, J.B. Muhlestein, J.F. Carlquist, B.D. Horne, T.L. Bair, B.A. Campbell, A.G. Kfoury, J.L. Lyon, H. Kim, and D.G. Renlund Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure Am J Cardiol 98 2006 653 658
18. I. Ananaba, and H. Taegtmeyer Low serum cholesterol as prognostic indicator in heart failure J Card Fail 18 2012 596
19. T.B. Horwich, G.C. Fonarow, M.A. Hamilton, W.R. MacLellan, M.A. Woo, and J.H. Tillisch The relationship between obesity and mortality in patients with heart failure J Am Coll Cardiol 38 2001 789 795
20. J.P. Araujo, F. Frioes, A. Azevedo, P. Lourenco, F. Rocha-Goncalves, A. Ferreira, and P. Bettencourt Cholesterol - a marker of nutritional status in mild to moderate heart failure Int J Cardiol 129 2008 65 68
21. G.C. Fonarow, P. Srikanthan, M.R. Costanzo, G.B. Cintron, M. Lopatin ADHERE Scientific Advisory Committee and Investigators An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry Am Heart J 153 2007 74 81
22. S. Arques, E. Roux, P. Sbragia, R. Gelisse, B. Pieri, and P. Ambrosi Usefulness of serum albumin concentration for in-hospital risk stratification in frail, elderly patients with acute heart failure. Insights from a prospective, monocenter study Int J Cardiol 125 2008 265 267
23. A.P. Ambrosy, M. Vaduganathan, M.D. Huffman, S. Khan, M.J. Kwasny, A.J. Fought, A.P. Maggioni, K. Swedberg, M.A. Konstam, F. Zannad, and M. Gheorghiade Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial Eur J Heart Fail 14 2012 302 311